These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6280840)

  • 1. Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung.
    Aroney RS; Bell DR; Chan WK; Dalley DN; Levi JA
    Cancer; 1982 Jun; 49(12):2449-54. PubMed ID: 6280840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
    Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Donnelly EJ; Raub WA
    Am J Clin Oncol; 1994 Dec; 17(6):527-37. PubMed ID: 7977175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
    Aisner J; Whitacre M; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Feb; 66(2):221-30. PubMed ID: 6275987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
    Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
    J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic alternating combination chemotherapy for small cell lung cancer.
    Reddy SK; Takita H; Lane WW; Vincent RG; Chen TY; Caracandas JE; Regal AM
    Cancer Chemother Pharmacol; 1984; 12(3):190-3. PubMed ID: 6323044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
    Cohen MH; Ihde DC; Bunn PA; Fossieck BE; Matthews MJ; Shackney SE; Johnston-Early A; Makuch R; Minna JD
    Cancer Treat Rep; 1979 Feb; 63(2):163-70. PubMed ID: 221114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
    Evans WK; Osoba D; Feld R; Shepherd FA; Bazos MJ; DeBoer G
    J Clin Oncol; 1985 Jan; 3(1):65-71. PubMed ID: 2981293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
    Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress and obstacles in chemotherapy and combined modality treatment of small cell lung cancer].
    Ohnoshi T; Ueoka H; Numata T; Kawahara S; Nishii K; Yonei T; Mima Y; Horiguchi T; Kiura K; Moritaka T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Feb; 28(2):190-6. PubMed ID: 2162437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
    J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.